Cargando…
Efficacy and safety of the fixed combinations of tafluprost/timolol and latanoprost/carteolol
In this study, we made a comparative efficacy and safety assessment of two different fixed combinations of drugs, viz., tafluprost/timolol (TAF/TIM) and latanoprost/carteolol (LAT/CAR), by determining their effects on intraocular pressure (IOP) in ocular normotensive monkeys and examining their toxi...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6522485/ https://www.ncbi.nlm.nih.gov/pubmed/31097790 http://dx.doi.org/10.1038/s41598-019-44028-2 |
_version_ | 1783419125972860928 |
---|---|
author | Fuwa, Masahiro Shimazaki, Atsushi Mieda, Masafumi Yamashita, Naoko Akaishi, Takahiro Taniguchi, Takazumi Kato, Masatomo |
author_facet | Fuwa, Masahiro Shimazaki, Atsushi Mieda, Masafumi Yamashita, Naoko Akaishi, Takahiro Taniguchi, Takazumi Kato, Masatomo |
author_sort | Fuwa, Masahiro |
collection | PubMed |
description | In this study, we made a comparative efficacy and safety assessment of two different fixed combinations of drugs, viz., tafluprost/timolol (TAF/TIM) and latanoprost/carteolol (LAT/CAR), by determining their effects on intraocular pressure (IOP) in ocular normotensive monkeys and examining their toxic effects on ocular surface using human corneal epithelial cells. TAF/TIM was found to be more effective in lowering IOP for a longer duration compared to LAT/CAR. We found that the difference in the intensity of IOP-lowering effect was because of the differences in the strength of timolol compared with that of carteolol as a beta-adrenergic antagonist and strength of tafluprost compared with that of latanoprost as a prostaglandin analogue. In addition, TAF/TIM showed much less cytotoxic effects compared to LAT/CAR on the human corneal epithelial cells. Our findings showed that TAF/TIM is better than LAT/CAR with regard to the IOP-lowering effect in monkeys and toxicity on ocular surface. |
format | Online Article Text |
id | pubmed-6522485 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-65224852019-05-28 Efficacy and safety of the fixed combinations of tafluprost/timolol and latanoprost/carteolol Fuwa, Masahiro Shimazaki, Atsushi Mieda, Masafumi Yamashita, Naoko Akaishi, Takahiro Taniguchi, Takazumi Kato, Masatomo Sci Rep Article In this study, we made a comparative efficacy and safety assessment of two different fixed combinations of drugs, viz., tafluprost/timolol (TAF/TIM) and latanoprost/carteolol (LAT/CAR), by determining their effects on intraocular pressure (IOP) in ocular normotensive monkeys and examining their toxic effects on ocular surface using human corneal epithelial cells. TAF/TIM was found to be more effective in lowering IOP for a longer duration compared to LAT/CAR. We found that the difference in the intensity of IOP-lowering effect was because of the differences in the strength of timolol compared with that of carteolol as a beta-adrenergic antagonist and strength of tafluprost compared with that of latanoprost as a prostaglandin analogue. In addition, TAF/TIM showed much less cytotoxic effects compared to LAT/CAR on the human corneal epithelial cells. Our findings showed that TAF/TIM is better than LAT/CAR with regard to the IOP-lowering effect in monkeys and toxicity on ocular surface. Nature Publishing Group UK 2019-05-16 /pmc/articles/PMC6522485/ /pubmed/31097790 http://dx.doi.org/10.1038/s41598-019-44028-2 Text en © The Author(s) 2019 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Fuwa, Masahiro Shimazaki, Atsushi Mieda, Masafumi Yamashita, Naoko Akaishi, Takahiro Taniguchi, Takazumi Kato, Masatomo Efficacy and safety of the fixed combinations of tafluprost/timolol and latanoprost/carteolol |
title | Efficacy and safety of the fixed combinations of tafluprost/timolol and latanoprost/carteolol |
title_full | Efficacy and safety of the fixed combinations of tafluprost/timolol and latanoprost/carteolol |
title_fullStr | Efficacy and safety of the fixed combinations of tafluprost/timolol and latanoprost/carteolol |
title_full_unstemmed | Efficacy and safety of the fixed combinations of tafluprost/timolol and latanoprost/carteolol |
title_short | Efficacy and safety of the fixed combinations of tafluprost/timolol and latanoprost/carteolol |
title_sort | efficacy and safety of the fixed combinations of tafluprost/timolol and latanoprost/carteolol |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6522485/ https://www.ncbi.nlm.nih.gov/pubmed/31097790 http://dx.doi.org/10.1038/s41598-019-44028-2 |
work_keys_str_mv | AT fuwamasahiro efficacyandsafetyofthefixedcombinationsoftafluprosttimololandlatanoprostcarteolol AT shimazakiatsushi efficacyandsafetyofthefixedcombinationsoftafluprosttimololandlatanoprostcarteolol AT miedamasafumi efficacyandsafetyofthefixedcombinationsoftafluprosttimololandlatanoprostcarteolol AT yamashitanaoko efficacyandsafetyofthefixedcombinationsoftafluprosttimololandlatanoprostcarteolol AT akaishitakahiro efficacyandsafetyofthefixedcombinationsoftafluprosttimololandlatanoprostcarteolol AT taniguchitakazumi efficacyandsafetyofthefixedcombinationsoftafluprosttimololandlatanoprostcarteolol AT katomasatomo efficacyandsafetyofthefixedcombinationsoftafluprosttimololandlatanoprostcarteolol |